Patents by Inventor Gretchen Snyder
Gretchen Snyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165111Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine Di and D2 receptor signaling system, and/or the wopioid receptor.Type: ApplicationFiled: November 6, 2023Publication date: May 23, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Patent number: 11980617Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.Type: GrantFiled: March 15, 2019Date of Patent: May 14, 2024Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Gretchen Snyder, Robert Davis, Lawrence P. Wennogle
-
Publication number: 20240122924Abstract: The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.Type: ApplicationFiled: November 22, 2023Publication date: April 18, 2024Inventors: Sophie DUTHEIL, Gretchen SNYDER, Peng LI, Robert E. DAVIS
-
Publication number: 20240059687Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: August 17, 2023Publication date: February 22, 2024Inventors: Peng LI, Hailin ZHENG, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Publication number: 20240009195Abstract: The disclosure provides methods, treatments and materials for treating diseases or disorders mediated by cyclic nucleotides and/or sodium glucose cotransporter 2. In particular, the present disclosure provides for methods of treating such diseases and disorders with a PDE1 inhibitor in combination with additional therapeutic agents.Type: ApplicationFiled: July 26, 2021Publication date: January 11, 2024Inventors: Peng LI, David KASS, Robert DAVIS, Gretchen SNYDER
-
Patent number: 11844757Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: GrantFiled: September 9, 2020Date of Patent: December 19, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
-
Publication number: 20230372336Abstract: The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.Type: ApplicationFiled: May 18, 2023Publication date: November 23, 2023Inventors: Sophie DUTHEIL, Gretchen SNYDER, Peng LI, Robert E. DAVIS
-
Patent number: 11773095Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: GrantFiled: July 19, 2022Date of Patent: October 3, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
-
Publication number: 20230181576Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: September 9, 2020Publication date: June 15, 2023Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Publication number: 20220372035Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: July 19, 2022Publication date: November 24, 2022Inventors: Peng LI, Hailin ZHENG, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Publication number: 20220362241Abstract: The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and/or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A/D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).Type: ApplicationFiled: September 25, 2020Publication date: November 17, 2022Inventors: Robert E. DAVIS, Gretchen SNYDER, Peng LI
-
Publication number: 20220296591Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: ApplicationFiled: June 3, 2022Publication date: September 22, 2022Inventors: Peng LI, Wei YAO, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Patent number: 11427587Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: GrantFiled: July 20, 2018Date of Patent: August 30, 2022Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
-
Patent number: 11376249Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: GrantFiled: July 20, 2018Date of Patent: July 5, 2022Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Wei Yao, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
-
Publication number: 20220184072Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment of neuropathic pain.Type: ApplicationFiled: April 4, 2020Publication date: June 16, 2022Inventors: Robert DAVIS, Gretchen SNYDER, Kimberly VANOVER
-
Patent number: 11291666Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, e.g., neuroinflammation, including methods of treatment and pharmaceutical compositions for use therein.Type: GrantFiled: September 12, 2017Date of Patent: April 5, 2022Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Gretchen Snyder, Lawrence P. Wennogle, Jennifer O'Brien, Joseph Hendrick
-
Publication number: 20220088014Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment or prevention of opiate addiction relapse.Type: ApplicationFiled: January 23, 2020Publication date: March 24, 2022Inventors: Peng LI, Wei YAO, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
-
Publication number: 20220072003Abstract: The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including for inhibiting tumor recruitment of macrophages and other cells to the tumor or cancer, for complementing and enhancing checkpoint inhibitor therapies, and for mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies.Type: ApplicationFiled: January 7, 2020Publication date: March 10, 2022Inventors: Gretchen SNYDER, Lawrence P. WENNOGLE, Jennifer O'BRIEN, Joseph HENDRICK, Robert DAVIS
-
Publication number: 20210338679Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.Type: ApplicationFiled: September 25, 2019Publication date: November 4, 2021Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Gretchen SNYDER, Lawrence P. WENNOGLE, Jennifer O'BRIEN, Joseph HENDRICK
-
Publication number: 20210213018Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, e.g., neuroinflammation, including methods of treatment and pharmaceutical compositions for use therein.Type: ApplicationFiled: September 12, 2017Publication date: July 15, 2021Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Gretchen SNYDER, Lawrence P. WENNOGLE, Jennifer O'BRIEN, Joseph HENDRICK
